

«Ενιαία υγεία και λοιμώξεις στη Λεκάνη της Μεσογείου/Οστικό Έλλειμμα και Λοίμωξη»

**ACUTE
DIARRHEAL
SYNDROMES**

CHOLERA

(Vibrio cholerae Infection)



Sympardi Styliani, MD, PhD
Infectious Disease Specialist
“THRIASION” HOSPITAL

Σύγκρουση Συμφερόντων Conflict of Interest Statement

ΚΥΡΙΟΣ ΕΡΕΥΝΗΤΗΣ ΣΕ:

- Διεθνή Μελέτη** του National Institute of Allergy and Infectious Diseases (NIAID)
- Ομαδική Κλινική Μελέτη** του Ελληνικού Ινστιτούτου Σήψης
- Ομαδική Κλινική Μελέτη** της Ελλην Εταιρείας Χημειοθεραπείας
- Τιμητικές αμοιβές για συμμετοχές σε Εκπαιδευτικές εκδηλώσεις και συμμετοχή σε εκπαιδευτικά συνέδρια από Φαρμακευτικές Εταιρείες Pfizer, Astellas, Angelini, MSD**

Τμήμα Επιδημιολογικής Επιτήρησης και Παρέμβασης


ΧΟΛΕΡΑ (ICD-10 A00)

- ➔ Η χολέρα είναι μια οξεία διαρροϊκή νόσος που οφείλεται στην προσβολή του εντέρου **από την εντεροτοξίνη** που παράγει το βακτήριο *Vibrio cholerae*
- ➔ Σύμφωνα με τον Π.Ο.Υ. **μόνο τα στελέχη του *Vibrio cholerae* των ορομάδων O1 και O139 που παράγουν τοξίνη** προκαλούν σοβαρή νόσο που χαρακτηρίζεται ως «χολέρα» και επιδημίες
- ➔ Κάθε ορομάδα έχει **2 βιότυπους τον Κλασικό & τον El-Tor**
- ➔ Κάθε βιότυπος έχει **3 οροτύπους Inaba, Ogawa & Hikojima**
- ➔ Οι υπόλοιπες οροομάδες του βακτηρίου τοξινογόνοι ή μη μπορούν να προκαλέσουν ήπιο διαρροϊκό σύνδρομο και δεν προκαλούν επιδημίες




NOBEL of Peace 1952
**Albert
Schweitzer**

Ιδρυση και τη συντήρηση νοσοκομείου στο
Λαμπαρανέ της Γκαμπόν, στην κεντροδυτική Αφρική.



Countries reporting cholera deaths and imported cases in 2016

Pays ayant déclaré des décès dus au choléra et des cas importés en 2016



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Les appellations employées dans la présente publication et la présentation des données qui y figurent n'impliquent de la part de l'Organisation mondiale de la Santé aucune prise de position quant au statut juridique des pays, territoires, villes ou zones, ou de leurs autorités, ni quant au tracé de leurs frontières ou limites. Les lignes discontinues et en pointillé sur les cartes représentent des frontières approximatives dont le tracé peut ne pas avoir fait l'objet d'un accord définitif.

Data Source: Control of Epidemic Diseases Unit
World Health Organization

Map Production: Information Evidence and Research (IER)
World Health Organization



World Health Organization

© WHO 2017. All rights reserved.




Organisation mondiale de la Santé

© OMS 2017. Tous droits réservés.



Cholera 101: Why This Ancient Disease Is Making Headlines In 2019

April 2, 2019 · 10:25 AM ET



The figure at left is the personification of cholera, facing resistance from a group of women. This 19th century engraving is from Barcelona.

Cyclone Idai: First cholera death in Mozambique as cases double

March 2019



Cholera is a Fast Killer & can kill a person in a matter of hours

Cyclone Idai, which hit on 14 March 2019, caused massive flooding and killed more than 700 people across southern Africa.

More than 500 cases of cholera have since been reported in Beira with cases of the disease almost doubling in Mozambique





Cholera Remains..

- A major public health problem
- Affects primarily developing world populations
- No proper access to adequate water and sanitation resources

GREECE

Δονάκιο χολέρας σε νεογέννητο που νοσηλεύεται
στο «Αγία Σοφία»



ΥΓΕΙΑ

18.10.2017, 19:54

**ΚΕΕΛΠΝΟ: Δεν υπάρχει
χολέρα στο «Έλενα
Βενιζέλου»**



- ➔ Η μέση δηλούμενη επίπτωση στις χώρες της Ευρωπαϊκής Ένωσης 2009, ήταν **<0,01 κρούσματα ανά 100.000 πληθυσμού**
- ➔ Στην Ελλάδα, η τελευταία επιδημία χολέρας καταγράφηκε το 1912-1913 (Βαλκανικοί πόλεμοι)
- ➔ Η χολέρα ανήκει στα νοσήματα άμεσης δήλωσης του συστήματος υποχρεωτικής δήλωσης νοσημάτων του ΕΟΔΥ (ΚΕΕΛΠΝΟ)

Map 1. Areas reporting cholera outbreaks 2010-2014




Cholera is under-reported

- 2.9 million cases
- 95,000 deaths are suspected to actually occur each year

Epidemiology

**Cholera cases reported to WHO by year and by continent
1989–2016**



Source: Weekly Epidemiological Record, 2017, 92(35)

Oceania Americas Asia Africa

©WHO. All right reserved.

Epidemiology

Cholera cases reported WHO worldwide

In 2016:

- 132121 cholera cases
- 2420 deaths
- Outbreaks continued to affect several countries
- 54% of cases were reported from Africa
- 13% from Asia
- 32% from Hispaniola

Epidemiology

In 2017:


Cholera continues to hit communities already made vulnerable by tragedies such as conflicts and famines



- **Yemen** currently faces the world's largest cholera outbreak, with over 700,000 suspected cases and **more than 2,000 deaths reported since April**
- **Somalia:** Over **800 people have died of cholera** since the beginning of the year, and over **500 in the DRC**
- **Haiti** has now reported nearly 1 million cases and 10,000 deaths **since the beginning of the 2010 outbreak**

**Yemen cholera outbreak
accelerates to 10,000+ cases
per week: WHO**

On May 22, the number of cases began a dramatic trend upward.



Water born Infection

Transmission

- **Cholera transmission is closely linked to inadequate access to clean water and sanitation facilities.**
- **Typical at-risk areas** include peri-urban slums, and camps for internally displaced persons or refugees, *where minimum requirements of clean water and sanitation are not been met.*
- The **consequences of a humanitarian crisis** – such as disruption of water and sanitation systems, or the displacement of populations to inadequate and overcrowded camps – can increase the risk of cholera transmission, should the bacteria be present or introduced.
- **People who are more likely to be exposed to cholera include:**
 - healthcare personnel
 - cholera response workers
 - travelers in an area of active cholera transmission *(who cannot or do not always follow safe food and water precautions and personal hygiene measures)*
- **Uninfected dead bodies have never been reported as the source of epidemics**

Epidemiology

Current climate





Fig. 4. Global map of *Vibrio cholerae* suitability in seawaters.

Model generated under the current climate scenario.



Vibrio cholerae interactions with other organisms and the environment:


V. cholerae is part of the bacterioplankton in aquatic environments.

It is under predation **pressure by protozoa and bacteriophage** and is thus incorporated into the microbial loop. Low temperature and nutrient conditions can trigger the VBNC state (*viable but nonculturable* (VBNC) bacteria refers to bacteria that are in a state of very low metabolic activity and do not divide, but are alive and have the ability to become culturable once resuscitated).

V. cholerae can also attach to autotrophic organisms such as **phytoplankton or macroalgae**, which can provide a carbon source. Attachment to chitinous **zooplankton and gelatinous egg masses** (e.g., chironomids) provide nutrients and also facilitate HGT (*Horizontal gene transfer*).

Fish and birds feed on plankton or mussels that might harbor *V.cholerae* and can potentially spread the bacterium across long distances.

Microbiology



- Class : Gamma Proteobacteria
- Order: Vibrionales
- Family: Vibrionaceae

- Genus: ***Vibrio***
 - Species: ***V. cholerae***
- Diarrhea

V. parahaemolyticus

V. fluvialis

V. mimicus

V. vulnificus

Vibrio spp

Primary Site of Infection.

Disease by Ingestion



❖ Extra-Intestinal Infection.

- *V. vulnificus*

❖ Intestinal Infection



- *V. parahaemolyticus* (TDH-TRH).
- *V. cholerae* (CTX-TCP).
- *V. mimicus*.
- *V. fluvialis*.

Disease by Contact



❖ Ear Infection



- *V. alginolyticus*

❖ Skin Injury



- *V. vulnificus* (Capsule-Hemolysins)
- *V. alginolyticus*

Microbiology



- Many serogroups of ***Vibrio cholerae***
- Only two – O1 and O139 – **cause outbreaks**
- ***V. cholerae* O:1** has caused all recent outbreaks
- ***V. cholerae* O:139** – first identified in Bangladesh in 1992 – caused outbreaks in the past. *It has never been identified outside Asia.*
- There is no difference in the illness caused by the two serogroups.

Microbiology

Vibrio cholerae Morphology

- Gram negative
- rigid, curved rods that are actively motile
- Comma shaped
- Sheathed, polar flagellum
- About $1.5 \times 0.2-0.4 \mu\text{m}$ in size






Figure IV-1. Overnight colonies of *V. cholerae* on TCBS because of the fermentation of sucrose. They are characteri slightly flattened.



Vibrio cholerae growing on thiosulphate citrate bile salt sucrose (TCBS) agar plates



Figure IV-3. Overnight growth of *V. cholerae* on MacConkey agar appears as small (1- to 3 mm), translucent, colorless-to-light pink (lactose-negative) colonies.

Diagnosis

✓ Confirmed by Culture or PCR

A suspected case with *Vibrio cholerae* O1 or O139 confirmed **by culture or PCR**

In countries where cholera is not present or has been eliminated, the *Vibrio cholerae* O1 or O139 strain is demonstrated to be toxigenic

✓ Rapid Tests

In areas with limited or no laboratory testing, the **Crystal® VC dipstick rapid test** can provide an early warning to public health officials that an outbreak of cholera is occurring *Sensitivity and specificity of this test is not optimal*. Recommended, **always be confirmed using traditional culture-based** methods suitable for the isolation and identification of *V. cholerae*

Table 1
Minimum inhibitory concentration (MIC) values of antibiotics for outbreak causing *V. cholerae* O1 biotype El Tor serotype Ogawa isolates in Kolkata, India.

Strains	MICs of antibiotics (μ g/mL)								
	Am	C	Tm	T	Er	Nx	Cp	Ak	Cfx
Resistant isolates	75–200	–	75–200	75–100	64–128	32–64	10	–	–
Sensitive isolates	2–4	2–8	–	4	2	4–8	0.66	2–4	2–8

Am = ampicillin, Ak = amikacin, C = chloramphenicol, Cfx = cefotaxime, Cp = ciprofloxacin, Er = erythromycin, Nx = nalidixic acid, Tm = trimethoprim, T = tetracycline.

Life Cycle

Cholera

Classed by the World Health Organization as a key indicator of lack of social development

Life cycle

3 Disruption of water and sanitation systems, displacement of populations to overcrowded camps increases risk

4 Passes into human digestive system through drinking or contaminated food

2 Organic pollutants such as human and animal waste can provide the nutrients to trigger epidemic of the bacteria

1 *V.cholerae* naturally occurs in aquatic sources such as wetlands, estuaries, and stagnant water, often associated with algal blooms



Vibrio cholerae bacteria

- Up to 5 million cholera cases annually worldwide
- 100,000 to 120,000 deaths a year

Infection

► Incubation period 2 hours to 5 days

► About 75 percent of infected people do not develop symptoms



► 20 percent of those showing symptoms develop acute watery diarrhoea and dehydration

► Can kill within hours if untreated, or successfully treated with rehydration salts, intravenous fluids

5 Exits body through faeces
Faeces can be contagious for up to 14 days




Life Cycle



Incubation periods: 1-5 days

Pathophysiology - Biochemistry


- O1 and O139 cholera bacteria strains secrete a toxin that contains **Cholera Toxin Subunit B (CTB)**
- **CTB binds to Ganglioside GM1** on the cell membranes of enterocytes and the toxin is internalized
- The **A1 domain** of the toxin's A subunit is cleaved and travels to the cytosol
- **A1 binds and activates Gsa**, locking it in its GTP form
- The GTP form of Gsa stimulates **adenylate cyclase (AC)**, which produces **cyclic AMP (cAMP)**



1. Ganglioside GM1. (2018). U.S. National Library of Medicine.

2. Lauer, S., et al (2002). Analysis of Cholera Toxin–Ganglioside Interactions by Flow Cytometry. *Biochemistry*. 41(6): 1742-1751

Mechanism of Action of Cholera Toxin



Mechanism → Symptoms

- cAMP binds to a transmembrane protein called **Cystic Fibrosis Transmembrane Regulator**, which releases **chloride ions** into the extracellular space
- Efflux of chloride ions **triggers efflux of sodium and water** as well, as cell tries to restore a balance in charge
- Efflux of abnormal amounts of water and ions from the intestine induces **watery diarrhea** (which causes dehydration and a decrease in blood volume), **cramps** (due to electrolyte imbalance), **hypovolemic shock** (due to decreased blood volume), and **vomiting** in the infected individual

Signs & Symptoms

Symptoms: *Watery diarrhoea, vomiting, thirst, dehydration, muscle cramps*

Complications: *Muscular pain, renal failure, pulmonary edema, cardiac arrhythmias*


¹ See page 21 for details on the case study and underlying assumptions.



How to choose a site for a CTC

Cholera Treatment Centers should be:

1. Where patients can easily access the facility
2. Located away from water sources and functioning facilities (e.g. schools, markets, dispensaries)
3. Separated from other patient wards, if located within an existing healthcare facility
4. Easy to clean



WHO GUIDELINES

Management of the patient with cholera

Steps in the management of suspected cholera:

- Step 1. Assess for dehydration.
 - Step 2. Rehydrate the patient, and monitor frequently. Then reassess hydration status.
 - Step 3. Maintain hydration: replace ongoing fluid losses until diarrhoea stops.
 - Step 4. Give an oral antibiotic to the patient with severe dehydration.
 - Step 5. Feed the patient.
-

Treatment Kit

The image displays a comprehensive treatment kit for cholera, arranged neatly on a light-colored floor. The items include:

- A white full-body protective suit with red trim and a hood.
- A box of green nitrile gloves.
- A red sharps disposal container.
- An orange box of Direct Relief Oral Rehydration Salts (ORS) with several sachets.
- A black stethoscope.
- A small box of urine test strips.
- A box of Bardia Urine Calipers.
- A clear plastic bag containing more gloves or wipes.
- A small box of pills or capsules.
- Three small bottles of medicine or disinfectant.
- A packet of instant noodle cups.



Cholera Treatment

- **Oral Rehydration Therapy (ORT)**

- **Timely administration of oral rehydration salts** can reduce the fatality rate to less than 1%

- For severe dehydration and hypovolemic shock, **intravenous fluids** (ex. Ringer's lactate) and **electrolytes** are required

- **Zinc Treatment**

- Recommended for use in cases of **pediatric diarrhea**
 - Helps reduce the duration of diarrhea and volume of stool
 - **Reduces cAMP** concentration

Table 1: Assessment and classification of cholera patients for dehydration

Degree of Dehydration	No dehydration	Some Dehydration	Severe dehydration
1. Look at:			
a. General condition	Well, alert	Restless, Irritable Fluid loss less than 10% of body weight	Lethargic or Unconscious / floppy Fluid loss more than 10% of body weight. Pulse: barely detectable.
b. Eyes	Normal	Sunken	Very sunken and dry
c. Tears	Present	Absent	Absent
d. Mouth and tongue	Moist	Dry	Very dry
e. Thirst	Not thirsty, drinks normally	Thirsty, drinks Eagerly	Drinks poorly or not able to drink
2. Feel	Skin pinch Goes back quickly	Goes back slowly (within 2 seconds) Care must be taken for the elderly persons	Goes back very slowly (more than 2 second) Care must be taken for the elderly persons
3. Decide	No sign of dehydration: (<5 percent) Plan A	The patient has two or more signs including at least one bold sign (5-10 percent) Plan B	The patient has two or more signs including at least one bold sign: (>10 percent) Plan C
4. Treatment	ORS plus health Education, counseling and rehabilitation observe for 4 hours then discharge on ORS, recommended antibiotics and zinc for children under 5 years	Oral rehydration with ORS, recommended antibiotic and zinc for children under 5 years, vigorous monitoring at CTU. Continue feeding	IV therapy plus recommended Antibiotics, and zinc for children under 5 years and ORS as soon as able to drink. Continue feeding

Minimal to No Dehydration – Plan A Treatment

ORS amounts to prevent dehydration (WHO recommendation)

Age	Amount of ORS after each loose stool	ORS quantity needed
Less than 24 months	50 to 100 ml	Enough for 500 ml / day (1 sachet)*
2 to 10 years	100 to 200 ml	Enough for 1000 ml / day (1 sachet)*
Over 10 years	as much as wanted	Enough for 2000 ml / day (2 sachets)*

(*) ORS bags are usually for 1 litre. In some countries, ORS bags are conditioned for less than 1 litre.

STEP 2

Moderate dehydration – Plan B

Treatment

ORS administration in the first 4 hours (generally 75ml x weight (kg))

- If unable to take oral, use NG tube
- Vomiting often ceases within 2-3 hours after dehydration has improved.
- If pt. is thirsty, administer more ORS
- Observe pt. to ensure required amount of ORS is administered
- If after 4 hours, pt. has signs of dehydration, use **Plan C**
- Monitor urine output

STEP 2**Rehydration protocol for Plan B**


Age	<5months	6—11 Months	12- 23months	2-4 yrs	5-14 yrs	15+ years
Weight	<5kg	5-7kg	8-10kg	11- 15kg	16-29kg	30+
ORS ml	200-400	400- 600	600-800	800- 1200	1200-2200	2200- 4000
Zinc tablet 20 mg (tab)	1/2 tab for 10 days	1 tab for 10 days	1 tab for 10 days	1 tab for 10 days	Not recommended	

IPET :
Solvazinc tab eff 125mg
Wilzin cap 50mg

Recommended for under-
five children only

Severe dehydration – Plan C Treatment

- Intravenous fluids



- Large bore 18 gauge IV needles
- Can use nasogastric tube if IV cannot be placed (20ml/kg 1st hour)

Source: CDC trainers of trainers presentation



Algorithm of Rehydration

SIGN OF DEHYDRATION

2 or more of the following signs?

1. sunken eyes
2. absence of tears
3. dry mouth and tongue
4. thirsty and drinks eagerly
5. Goes back slowly(< 2 sec)

If NO

No dehydration
(<5 percent)

Oral Rehydration

If YES

2 or more of the following signs?

1. lethargic, unconscious or floppy
2. unable to drink
3. radial pulse is weak
4. Goes back very slowly(>2 sec)

If NO

Some dehydration
(5-10 percent)

ORS solution to give in the first 4 hours

If improv

If YES

Severe
dehydration
(>10 percent)

Age	Amount After Loose Stool
< 24 mo	50-100 mL
2-9 y	100-200 mL
>10 y	As much as is wanted

Age	< 4 mo	4-11 mo	12-23 mo	2-4 y	5-14 y	>15 y
Weight	< 5 kg	5-7.9 kg	8-10.9 kg	11-15.9 kg	16-29.9 kg	>30 kg
ORS solution in mL	200-400	400-600	600-800	800-1200	1200-2200	2200-4000

Cholera Treatment

- **Oral Rehydration Therapy (ORT)**

- **Timely administration of oral rehydration salts** can reduce the fatality rate to less than 1%

- For severe dehydration and hypovolemic shock, **intravenous fluids** (ex. Ringer's lactate) and **electrolytes** are required

- **Zinc Treatment**

- Recommended for use in cases of **pediatric diarrhea**
 - Helps reduce the duration of diarrhea and volume of stool
 - Reduces **cAMP** concentration

Organization	Recommendation	drug choice	choices	Drug choices for special populations
World Health Organization ²¹	Antibiotic treatment for cholera patients with severe dehydration only	Doxycycline 300mg single dose	Tetracycline 500mg x 4 x 3d	Erythromycin is recommended drug for children 12,5 mg/kr x 4 x 3d children
Pan American Health Organization ²²	Antibiotic treatment for cholera patients with moderate or severe dehydration	Doxycycline 300mg single dose	Ciprofloxacin 1gr* Azithromycin 1gr* *single dose	Erythromycin or azithromycin recommended as first-line drugs for pregnant women and children Ciprofloxacin and doxycycline recommended as second-line drugs for children
International Centre for Diarrhoeal Disease Research, Bangladesh ²³	Antibiotic treatment for cholera patients with some or severe dehydration	Doxycycline 300mg single dose	Ciprofloxacin 1gr* Azithromycin 1gr* Cotrimoxazole *single dose	Erythromycin recommended as first-line drug for children and pregnant women 500mg x 4 x 3d Pregnant women
Medicins Sans Frontieres ²⁴	Antibiotic treatment for severely dehydrated patients only	Doxycycline 300mg single dose	Erythromycin Cotrimoxazole Chloramphenicol Furazolidone	




Table 3. Multivariate Logistic-Regression Analysis of Variables Predicting Clinical Failure of Therapy among 195 Patients with Cholera Treated with Azithromycin or Ciprofloxacin.*

Variable	Odds Ratio (95% CI)	P Value
Ciprofloxacin treatment (vs. azithromycin)	10.2 (4.8–21.5)	<0.001
No. of stools before admission†	1.1 (1.0–1.1)	0.02
Stool volume during 4-hr observation period‡	1.1 (1.1–1.2)	0.002

* Variables that were considered in the model were treatment received, the duration of illness before admission, the number of stools after the onset of illness and before admission, the weight on arrival, the change in weight between arrival and full hydration, the serum creatinine level, and the volume and numbers of stool during the observation period. CI denotes confidence interval.

† For each additional stool before admission, the risk of clinical failure increased by an odds ratio of 1.1.

‡ For each additional milliliter of stool per kilogram of body weight per hour, the risk of clinical failure increased by 1.1.

Vibrio cholerae - Resistance

Many studies emphasize the critical problem of increasing antimicrobial resistance

➔ In Bangladesh and elsewhere, has developed **substantial antimicrobial resistance to:**

- Trimethoprim–sulfamethoxazole
- Furazolidone
- Tetracycline

➔ **Resistance is emerging to:**

- Ciprofloxacin
- Azithromycin

<http://www.cdc.gov/cholera/index.html>

1. Khan WA, Bennis Mlet al.. Comparison of single-dose azithromycin for childhood cholera: a randomized, double-blind trial. *Lancet*. 2002;360:1722-7.

2. Saha D, Bennis Mlet al. . Single-dose azithromycin for the treatment of cholera in adults. *N Engl J Med*. 2006;354(23):2452-62

Cholera Therapy - What Not To Use



Mass chemoprophylaxis

- Mass administration of antibiotics to the community is NOT recommended in controlling a cholera outbreak as it may worsen the situation through false confidence.
- Nevertheless, chemoprophylaxis may be useful when a cholera outbreak occurs in a closed population, such as a prisons, mental health institutions, child care homes, boarding schools, barracks (police and army), IDP/Refugee camps.

OUTCOMES

More likely to have severe disease from cholera and suffer poor outcomes:

- ➔ Individuals with **achlorhydria**
- ➔ Blood **type O**
- ➔ **Chronic medical** conditions
- ➔ Those **without ready access to rehydration therapy** and medical services

Prevention




Oral Cholera Vaccine Campaign For People 1 Year and Above

In Landslide and Flood Affected Communities

Dates: 1st Dose - 15th – 20th September, 2017
2nd Dose – 5th – 10th October, 2017



Protect yourself and your family from cholera! Take two doses of the vaccine, drink safe water and practice proper hygiene!



Prevention

- **Oral Vaccines (offer incomplete protection)**

- **Bivalent killed whole-cell vaccine (Sanchol)** ASIA
 - contains serotypes of *V. cholerae* O1 and **O139** without the toxin B subunit
- **WC/rBS cholera vaccine (Dukoral)** → Out of ASIA
 - contains serotypes of *V. cholerae* O1 and recombinant cholera toxin B subunit
- **Lyophilized CVD 103-HgR (Vaxchora)**, a single-dose **live oral** cholera vaccine, *approved by FDA in 2016 ~ (3 mo 80% protection)*

- Drink and use **safe water** (water that is bottled, has been boiled, or has been treated with a chlorine product)
- **Wash your hands** often
- **Cook your food (especially seafood) well** and keep it covered
- **Clean up safely**

Acute diarrhoeal disease in complex emergencies

CRITICAL ST

Decision-making for preparedness and response

THE PURPOSE

This leaflet is designed to

- Identify key issues relevant

CHOLERA OUTBREAK

ASSESSING THE OUTBREAK RESPONSE AND IMPROVING PREPAREDNESS

First steps managing outbreak of acute diarrhoea

LET AIMS AT GUIDING YOU THROUGH
RY FIRST DAYS OF AN OUTBREAK

Emergencies regarding acute diarrhoea exist:

Cholera = acute watery diarrhoea
and

a dysentery = acute bloody diarrhoea

transmitted by contaminated water, unsafe food, hands and vomit or stools of sick people.

Cases of diarrhoea may produce severe illness in the individual, but will not produce outbreaks which pose an immediate threat to the community.




World Health Organization





Figure 1: Theory of change of the *Global Roadmap*



SUMMARY

Description: Infectious disease caused by ingestion of contaminated food containing bacterium *Vibrio cholerae*

- 2 strains of *Vibrio cholerae* causes outbreak - **O1** and **O139**
- Symptoms (if any) include: vomiting, leg cramps and watery diarrhea

Treatment:

- ✓ Oral Rehydration Therapy is the first-line treatment
- ✓ Doxycycline or tetracycline for adults
- ✓ Azithromycin for children and pregnant women can be used as an adjunctive therapy

Prevention: use **safe water** (boiled or water treated with a chemical disinfectant), cook your food well and eat it hot, wash your hands often, consider vaccination (**Sanchol** and **Dukoral** or **Vaxchora** [USA])

Ending Cholera—A Global Roadmap to 2030 operationalises the new global strategy for cholera control at the country level and provides a concrete path toward a world in which cholera is no longer a threat to public health



Σας ευχαριστώ για τη προσοχή σας

